Loading...
•
Mar 31, 2021
Aytu BioScience Q3 2021 Earnings Report
Aytu BioPharma reported financial results for the fiscal third quarter ended March 31, 2021 and provided recent business highlights.
Key Takeaways
Aytu BioPharma reported a net revenue of $13.5 million for Q3 2021, compared to $8.2 million in the same quarter last year. The company's net loss was $25.5 million, or $1.41 per share, which included Neos merger-related expenses and inventory write-offs.
Closed merger with Neos Therapeutics, creating a proforma combined $100 million revenue specialty pharmaceutical company.
Added late-stage pediatric onset rare disease asset, protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) to development pipeline
Consumer health division revenue reached a record $8.4 million.
Rx division revenue increased by 9% over the same quarter last year.
Aytu BioScience
Aytu BioScience
Forward Guidance
Aytu BioPharma anticipates several milestones and events for calendar year 2021 and 2022.
Positive Outlook
- Continue discussions with the FDA and other regulatory agencies regarding the advancement of its Healight™ UVA light catheter technology.
- Initiate Phase 2 trial of Healight in COVID-19 in second half of 2021.
- Announce multiple new product launches for the consumer health segment in the second half of 2021.
- Integrate sales forces and Neos RxConnect, to be rebranded as Aytu RxConnect, in the second half of 2021.
- Participate in Jefferies Virtual Healthcare Conference on Tuesday, June 1st and the Raymond James Human Health Innovation Conference on Wednesday, June 23rd.